PROJECT PEOPLE EVENTS NEWS JOBS CONTACT INTRANET
NANODRUG


NOVEL NANOPARTICLES FOR DRUG DELIVERY TO THE SKIN

NANODRUG is a research project funded by the European Commission, Marie Curie Actions, Seventh Framework Programme, Initial Training Network.

The aim of the NANODRUG Network is to contribute to the defragmentation of the emerging field of nanomedicine by providing a unique training programme that will cover all different aspects ranging from nanoparticles synthesis and characterisation, drug delivery, molecular biology to nanotoxicology, preclinical studies, risk assessment and nanotechnology policy making.

The scientific aim of the NANODRUG research training network is to develop and characterise a selected set of novel intelligent nanomaterials and to study their suitability as novel drug delivery systems targeting inflammatory skin diseases. The development and use of the nanoparticles described in this project aims to overcome the current difficulties that limit the applications of nanoparticles to skin drug delivery. The unique physicochemical properties of these novel nanoparticles such as ultra small size, large surface to mass ratio, high reactivity and the capability to tailor them to applications will ensure that when complexed with drugs the pharmacokinetics and therapeutic index of the delivery systems can be significantly improved compared to the free molecules and the capability to pass the SC of the skin greatly enhanced.

This project brings together six academic groups and two industrial teams as full partners, complemented by three associate partners, one of which is an industrial team, distributed over a total of six European Union member states and one non-ICPC country. The consortium brings together groups with a very interdisciplinary expertise ranging from polymer synthesis and characterisation, computational modelling and physicochemical characterisation of materials to bioavailability, nanoparticles formulation, drug distribution and nanotoxicity, genetics, drug delivery and clinical dermatology.

NANODRUG LOGO European Commission
Research funded by the European Commission - Marie Curie Actions
Seventh Framework Programme - The People Programme - Initial Training Network

grant agreement number 289454
2011-2015
  Marie Curie Actions
Copyright NANODRUG